Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 EPS without NRI is €-0.28 as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 54.2% on this metric.
VISEN Pharmaceuticals's earnings per share without non-recurring items for the
six
months ended in Jun. 2026 was €-0.12.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.28.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 7.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for VISEN Pharmaceuticals's EPS without NRI or its related term are showing as below:
FRA:T06'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 7.5 Med: 7.5 Max: 7.5
Current: 7.5
During the past 4 years, VISEN Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 7.50% per year. The lowest was 7.50% per year. And the median was 7.50% per year.
FRA:T06's 3-Year EPS without NRI Growth Rate is ranked worse than 54.2% of 786
companies
in the Drug Manufacturers industry
Industry Median: 9.9
vs FRA:T06: 7.50
VISEN Pharmaceuticals (FRA:T06) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
VISEN Pharmaceuticals EPS without NRI Related Terms
VISEN Pharmaceuticals EPS without NRI Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (FRA:T06) has a EPS without NRI of €-0.28 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on VISEN Pharmaceuticals and its competitors. According to the industry distribution chart, VISEN Pharmaceuticals ranks #426 out of 786 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is VISEN Pharmaceuticals' EPS without NRI too high?
VISEN Pharmaceuticals' current EPS without NRI is €-0.28. Based on the distribution chart, VISEN Pharmaceuticals ranks #426 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' EPS without NRI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #426 out of 786 companies for EPS without NRI. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.90, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current EPS without NRI is €-0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current EPS without NRI of €-0.28. The current EPS without NRI is €-0.28. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current EPS without NRI is €-0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
